Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

Texas Attorney General Ken Paxton alleges that Eli Lilly bribed Texas medical providers to provide the company's drugs. Eli Lilly denies the claims.

Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...

Lilly’s shares were impacted after a difficult month for its weight loss drug, A recent study showed the pill form of Lilly's ...

As part of a new campaign, Whitley is partnering with Zepbound to break down the stigma surrounding obesity and inspire others to seek support and treatment.